Compare Ferrari NV (RACE) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Tenet Healthcare Corporation — how do they compare? Ferrari NV trades at $389.63 (market cap $67.35B), while Tenet Healthcare Corporation trades at $260 (market cap $20.98B). The key difference: Ferrari NV is far larger — about 3.2× Tenet Healthcare Corporation's market cap, and Ferrari NV pays a 1.09% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and Tenet Healthcare Corporation for 15 Days on average.
| RACE | THC | |
|---|---|---|
Market Cap | $67.35B | $20.98B |
Volume | 390,618 | 428,008 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $280.77 |
52-Week Low | $314.63 | $161.37 |
Typical Hold Time | 126 Days | 15 Days |
Enterprise Value | $69.22B | $32.06B |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $386.39, down slightly by 0.03% today. The stock shows strong fundamentals with consistent earnings beats (Q4 2025: $2.49 vs. $2.44 expected, Q1 2026: $2.73 vs. $2.70 expected, Q2 2026: $2.99 vs. $2.83 expected) and robust profitability (net margin 22.25%, ROE 45.45%). Technical indicators are bearish overall, with the current price near support at $385. Recent news highlights a share buyback program and partnership with Rakuten effective January 2027.
Outlook: Analyst consensus is bullish with a $462.75 price target (73.69% buy ratings). Opportunities include strong brand equity, margin expansion, and strategic initiatives. Risks involve high valuation multiples (P/E 37.19, P/S 8.25), economic sensitivity, and execution of growth plans. The stock offers growth potential but requires monitoring of valuation and market conditions.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (ROE 53.31%, net margin 9.9%). Recent news highlights strong cash flow supporting capital returns and upcoming Q3 2026 results on October 29. Valuation appears reasonable with P/E of 10.07 and EV/EBITDA of 5.75.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and 7% upside to consensus target of $283.36. Key catalysts include sustained earnings momentum and efficient capital allocation. Risks include surgical volume pressures and cash flow sustainability concerns amid aggressive buybacks. The stock's current technical setup near pivot point $259 suggests balanced risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
